Q1 FY 2020 Conference call Presentation - August 14, 2019 - Neptune Wellness ...

Page created by Thelma Rios
 
CONTINUE READING
Q1 FY 2020 Conference call Presentation - August 14, 2019 - Neptune Wellness ...
Q1 FY 2020
                              Conference call
                               Presentation

                                              August 14, 2019

NASDAQ/TSX: NEPT ▫ Headquartered in Laval, Quebec, Canada
                                                                1
Q1 FY 2020 Conference call Presentation - August 14, 2019 - Neptune Wellness ...
DISCLAIMER

CAUTION REGARDING NON-IFRS FINANCIAL MEASURES
The Corporation uses two adjusted financial measures, Adjusted Segment Earnings Before Interest, Taxes, Depreciation and Amortization (Adjusted
Segment EBITDA) and Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA) to assess its operating performance.
These non-IFRS financial measures are directly derived from the Corporation’s financial statements and are presented in a consistent manner. The
Corporation uses these measures for the purposes of evaluating its historical and prospective financial performance, as well as its performance relative to
competitors. These measures also help the Corporation to plan and forecast for future periods as well as to make operational and strategic decisions. The
Corporation believes that providing this information to investors, in addition to IFRS measures, allows them to see the Corporation’s results through the
eyes of management, and to better understand its historical and future financial performance.

Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than IFRS do not have
standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in
isolation. The Corporation uses Adjusted Segment EBITDA and Adjusted EBITDA to measure its performance from one period to the next without the
variation caused by certain adjustments that could potentially distort the analysis of trends in our operating performance, and because the Corporation
believes it provides meaningful information on the Corporation’s financial condition and operating results. Neptune’s method for calculating Adjusted
Segment EBITDA and Adjusted EBITDA may differ from that used by other corporations.

Neptune obtains its Adjusted Segment EBITDA measurement by adding depreciation and amortization and stock-based compensation to segment income
(loss) from operating activities before corporate expenses. Neptune obtains its Adjusted EBITDA measurement by adding to net income (loss), net finance
costs and depreciation and amortization and by subtracting income tax recovery. Other items such as stock-based compensation, litigation provisions,
acquisition costs and severance and related costs that do not impact core operating performance of the Corporation are also added back as they may vary
significantly from one period to another. Adjusting for these items does not imply they are non-recurring.

                                                                                                                                                              2
Q1 FY 2020 Conference call Presentation - August 14, 2019 - Neptune Wellness ...
DISCLAIMER

CAUTION REGARDING FORWARD-LOOKING STATEMENTS
Statements in this presentation that are not statements of historical or current fact constitute ‟forward-looking statements” within the meaning of the
U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other
unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or
implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to
consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," "should," or "plans" to be uncertain and
forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this
presentation. Forward-looking information in this presentation includes, but is not limited to, information or statements about our ability to successfully
develop, produce, supply, promote or generate any revenue from the sale of any cannabis-based and hemp-based products in the legal market.

The forward-looking statements contained in this presentation are expressly qualified in their entirety by this cautionary statement and the ‟Cautionary
Note Regarding Forward-Looking Information” section contained in Neptune’s latest Annual Information Form (the ‟AIF”), which also forms part of
Neptune’s latest annual report on Form 40-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on
the Investors section of Neptune’s website at www.neptunecorp.com. All forward-looking statements in this presentation are made as of the date of this
presentation. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or
otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that
are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities
commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under ‟Risk Factors”.

                                                                                                                                                              3
Q1 FY 2020 Conference call Presentation - August 14, 2019 - Neptune Wellness ...
AGENDA

 Q1 FY2020 Corporate Highlights
 Q1 FY2020 Financials Highlights
 Update on Canadian expansion (Phase II & IIIA)
 SugarLeaf acquisition
 Outlook & Vision of New Leadership
 Q&A

                                                  4
Q1 FY 2020 Conference call Presentation - August 14, 2019 - Neptune Wellness ...
CORPORATE HIGHLIGHTS

3-year contract with Tilray to extract a minimum of
125,000 kg of biomass
3-year agreement with TGOD for extraction and
turnkey packaging solutions
On June 17, Neptune received a license amendment
at its Sherbrooke facility

                                                      5
Q1 FY 2020 Conference call Presentation - August 14, 2019 - Neptune Wellness ...
FINANCIAL HIGHLIGHTS

Nutraceutical revenues for Q1FY20 of $4.3 million, decreased slightly vs $5.2
million in Q1FY19
Cannabis revenues were impacted by capacity constraints
Net loss of $6.5 million for Q1FY20 versus a net loss of $4.1 million in Q1FY20
Q1FY20 Adjusted EBITDA loss of $3.6 million compared to Q1FY19 Adjusted EBITDA
loss of $2.3 million, reflecting investments in our cannabis operations

                                                                                  6
Q1 FY 2020 Conference call Presentation - August 14, 2019 - Neptune Wellness ...
CLOSING OF US$41M PRIVATE PLACEMENT

Strengthen our balance sheet
    Pro-Forma cash balance of C$39m
                                                                                                                         Capital Structure
    Successful financing realized in a difficult macro context
                                                                                     Fully Diluted Common Shares                                                        115,084,273
Perceptive Advisors were the lead participant
    Solid endorsement from our main shareholder                                      Fully Diluted Market Cap (C$6.57)                                                C$756,104,000

                                                                                     Pro-Forma Cash Position¹                                                         C$38,975,000¹
Strong participation by management & Directors
    Chairman & CEO invested $5m                                                      Total Debt²                                                                       C$4,567,445²
    Aligns leadership with shareholders

                  ¹Pro-forma Neptune’s US$41m private placement and the US$12m initial cash consideration paid to acquire the assets of SugarLeaf Labs with related
                  transaction costs
                  ² As at June 30, 2019

                                                                                                                                                                                 7
Q1 FY 2020 Conference call Presentation - August 14, 2019 - Neptune Wellness ...
CANADIAN CAPACITY EXPANSION UNDERWAY

  Phase II capacity is expected to increase capacity by ~7x
     Cold ethanol equipment to be commissioned in coming weeks
     Capacity to increase from 30,000 kg to 200,000 kg

  Initiating Phase IIIA expansion of ~1,300,000 kg
    Retrofit expected to be completed by calendar year-end
    Health Canada approval expected thereafter

  Capacity expansion expected to translate into significant
  revenue growth in coming quarters

  Phase II expansion fully committed

                                                                 8
Q1 FY 2020 Conference call Presentation - August 14, 2019 - Neptune Wellness ...
SUGARLEAF – NEPTUNE’S ENTRY INTO THE
               U.S. MARKET
Provides a platform to capture the CBD wellness opportunity in the US
     Tolling services, formulation, blending
     Complete white label turnkey solutions
     Forest Remedies our B2C brand

Cold ethanol technology produces high quality extracts
     Broad spectrum extracts and refined full spectrum extracts are in high demand
     Rigorous testing protocols to ensure traceability back to the farm

Acquisition closed on July 24, 2019
     Initial consideration of US$18m which could reach US$150m with performance
     milestones
     Purchase price would represent a 5x EBITDA multiple

Capacity expected to reach 1,500,000 kg by December 2019
     Opportunity to further expand if warranted
                                                                                     9
Q1 FY 2020 Conference call Presentation - August 14, 2019 - Neptune Wellness ...
STRONG EARNINGS POWER

   Existing facilities could support in excess of $450 million in revenues
       Long-term contracts provide revenue visibility
       Assuming a conservative 50% capacity utilization rate

   Adjusted EBITDA margins could exceed 40%
       High automation at Sherbrooke facility expected to reduce operational costs

   Expansion plans fully funded

                                                                               10
VISION & STRATEGY FORWARD

Vision  Become a leading supplier of cannabis and hemp extracts ingredients and finished products

Strategy
       Establish large scale extraction capabilities in Canada and the United-States

       Innovate and acquire unique delivery forms and technologies

       Invest in product development to create new verticals

       Focus on the Health & Wellness and CPG sectors

       Create an incubator of technologies with Neptune Ventures

                                                                                                     11
APPENDIX
Financial Information

                        12
FINANCIAL RESULTS

Income Statement                                                                                                Q1 FY2020 (1)
(in thousands of CAD $)
                                                                 Nutraceutical                     Cannabis                      Corporate                         Total
Revenues                                                              4,293                            38                             30                           4,361
Adjusted EBITDA                                                          530                        (1,623)                        (2,490)                        (3,583)
Net income (loss)                                                                                                                      -                          (6,452)

Income Statement                                                                                                Q1 FY2019 (1)
(in thousands of CAD $)
                                                                 Nutraceutical                     Cannabis                      Corporate                         Total
Revenues                                                              5,168                             -                              -                           5,168
Adjusted EBITDA                                                         633                         (1,302)                        (1,588)                        (2,257)
Net income (loss)                                                                                                                      -                          (4,100)

(1) Nutraceutical and Cannabis are two segments of Neptune. The corporate column represents unallocated costs which are corporate G&A expenses, net finance costs and income taxes.

                                                                                                                                                                                      13
FINANCIAL POSITION

Financial Position                                  June 30, 2019   March 30, 2019
(in thousands of CAD $)

Cash, cash equivalents and short-term investments      5,375            9,867

Total debt                                             4,567            3,467

Net proceeds from the private placement                51,600             -

Initial cash consideration for SugarLeaf ¹            (18,000)            -

Proforma net cash position                             34,408           6,400

(1) Includes transaction costs

                                                                                     14
Bringing Decades of
Wellness and Nutrition
Experience to the
Cannabis Industry

                         15
You can also read